Furthermore, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, monoclonal antibodies used in the therapy of hypercholesterolemia, and its related cardiovascular diseases were found to reduce both cholesterol and, potentially, ceramide levels and were suggested as a new therapeutic option for the treatment of dyslipidemia [62,67]. The gene discussed is PCSK9; the disease is metabolic syndrome.